1Q23 Business Results
RemsimaⓇSC (2/2)
✓ Prescriptions of RemsimaⓇSC has increased based on the accumulation of annual real-world data which shows positive response
from the patients
PK levels of RemsimaⓇSC switching patients
Achievement of Clinical Remission in CD&UC
20
15
Serum infliximab levels, µg/dl
10
un
=
H
H
0
Baseline
3m
6m
12m
PBO 0.04
0.00
VDZ SC 108 mg Q2W*
0.16
0.68
VDZ IV 300 mg Q4W*
047
0.63
VDZ IV 300 mg Q8W*
0.61
055
IFX IV 3.5 mg/kg Q8W N/A
IFX IV 5 mg/kg Q8W
0.38
0.49
0.35
IFX IV 10 mg/kg Q8W
0.81
0.59
RemsimaⓇ 120 mg Q2W
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
g
1Q23 Business Results
Key Products
Plan & Vision
Appendix
091
0.82
0.9
1.0
Investor Relations 2023 8
Note: Measured every 3 months after the switching. PK level of Infliximab has been maintained high and stable.
Source: Philip J Smith et al. Efficacy and Safety of Elective Switching From Intravenous to Subcutaneous Infliximab
(Ct-P13): A Multi-Centre Cohort Study, Journal of Crohn's and Colitis, 2022; jac053,
https://doi.org/10.1093/ecco-jcc/jjac053
Note: Higher scores correspond to a higher ranking for achieving clinical remission.
Source: L Peyrin-Biroulet, et al. P445, Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous
infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn's Disease and Ulcerative Colitis. J
Crohns Colitis. 2023;17(Suppl 1): 1574-1576View entire presentation